ABSTRACT # 1191

TRILACICLIB, A CDK4/6 INHIBITOR, DOSED WITH GEMCITABINE, CARBOPLATIN IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (mTNBC) PATIENTS: PRELIMINARY PHASE 2 RESULTS

JOYCE O’SHEAGHNESSY, GAIL S. WRIGHT, ANU R. TRUMBMEL, MICHAEL A. DANG, LAZAR POPOVIC, TIMOTHY J. PLUARD, ERIC CHIENG, HYF SONG HWI, BRODER R. DANIELS, ZELENO VUROVIC, NIKOLA VAZEE, LIN MA, DONALD R. RICHARDS, JR., STEVE T. WILDE, DYLAN KLEENEMINIC, KELLI M. WALTERS, JAMES A. SCHENKEL, JESSICA P. ROBERTS, MALINDA J. MILLER, SHAWN D. MOBERLY, ZIYAN YANG, JOYCE M. AKERS, LEANDER K. MILLER, ANTONETTE R. TAR, TESSA ONCLOGY BAYLOR SCARLENE, US ONCOLOGY RESEARCH; FLORIDA CANCER SPECIALISTS (MIRAS); COMPREHENSIVE CANCER CENTER OF NEVADA, US ONCOLOGY RESEARCH; PREUMA ONCOLOGY ASSOCIATES, US ONCOLOGY RESEARCH; ONCOLOGY INSTITUTE OF VIFSFINOA, UNIVERSITY OF HONOLULU, HAWAII; SANT LUCIA'S CANCER INSTITUTE; INNOVATIVE CLINICAL RESEARCH INSTITUTE; ONCOLOGY CANCER CENTER; TENNESSEE ONCOLOGY - CANTERBURY; COUNTY HOSPITAL VASTRO Cin, VA; ONCOLOGY RESEARCH; TESSA ONCOLOGY SAN ANTONIO, US ONCOLOGY RESEARCH; CLINICAL CENTER REIL, CINCINNATI, OH; G1 THERAPEUTICS; LEBANON CANCER INSTITUTE, ARIZON HEALTH

BACKGROUND

• Phase 3, open-label, global, multicenter, randomized, placebo-controlled, double-blind study of trilaciclib, a new chemotherapeutic sensitizer and hematopoietic stem/progenitor cell (HSPC) sparing agent, in combination with gemcitabine and carboplatin in patients with mTNBC
• Patients were randomized in a 2:2:1 ratio to GC + trilaciclib (Group 1), GC alone (Group 2), or GC + placebo (Group 3)
• Similar demographic data were observed across the groups: mean age (55-58 years), race distribution (66.7-82.4%), tumor grade (2.7-2.9), percentage basal-like (20-23% of patients)

STUDY DESIGN

• Safety was the primary endpoint
• Overall response rate (ORR) and progression-free survival (PFS) were secondary endpoints

RESULTS

• Overall demographic data are similar across the groups: mean age (55-58 years), race distribution (66.7-82.4%), tumor grade (2.7-2.9), percentage basal-like (20-23% of patients)
• Phase 2, open-label, global, multicenter, randomized, placebo-controlled, double-blind study of trilaciclib, a new chemotherapeutic sensitizer and hematopoietic stem/progenitor cell (HSPC) sparing agent, in combination with gemcitabine and carboplatin in patients with mTNBC

CONCLUSIONS

• The addition of trilaciclib to GC decreases the rate of dose modification events over time with minimal myelosuppression across multiple lineages

ACKNOWLEDGMENTS

On behalf of the investigators of the phase 2 study for the study presented in this abstract.